206 related articles for article (PubMed ID: 18566690)
21. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.
Chinetti G; Fruchart JC; Staels B
Inflamm Res; 2000 Oct; 49(10):497-505. PubMed ID: 11089900
[TBL] [Abstract][Full Text] [Related]
23. Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives.
Laganà AS; Vitale SG; Nigro A; Sofo V; Salmeri FM; Rossetti P; Rapisarda AM; La Vignera S; Condorelli RA; Rizzo G; Buscema M
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347932
[TBL] [Abstract][Full Text] [Related]
24. Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.
Tan CK; Zhuang Y; Wahli W
Expert Opin Ther Targets; 2017 Mar; 21(3):333-348. PubMed ID: 28092722
[TBL] [Abstract][Full Text] [Related]
25. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
Takada I; Makishima M
Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
[No Abstract] [Full Text] [Related]
27. PPAR alpha, fibrates, lipid metabolism and inflammation.
Duval C; Fruchart JC; Staels B
Arch Mal Coeur Vaiss; 2004 Jun; 97(6):665-72. PubMed ID: 15283041
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
Kasuga J; Makishima M; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2006 Feb; 16(3):554-8. PubMed ID: 16275077
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
Nomura M; Tanase T; Ide T; Tsunoda M; Suzuki M; Uchiki H; Murakami K; Miyachi H
J Med Chem; 2003 Aug; 46(17):3581-99. PubMed ID: 12904063
[TBL] [Abstract][Full Text] [Related]
30. Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis.
Lamichane S; Dahal Lamichane B; Kwon SM
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29565812
[TBL] [Abstract][Full Text] [Related]
31. Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes.
Ibabe A; Herrero A; Cajaraville MP
Toxicol In Vitro; 2005 Sep; 19(6):725-35. PubMed ID: 15964169
[TBL] [Abstract][Full Text] [Related]
32. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
Mansour M
Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
[TBL] [Abstract][Full Text] [Related]
33. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid.
Westergaard M; Henningsen J; Svendsen ML; Johansen C; Jensen UB; Schrøder HD; Kratchmarova I; Berge RK; Iversen L; Bolund L; Kragballe K; Kristiansen K
J Invest Dermatol; 2001 May; 116(5):702-12. PubMed ID: 11348458
[TBL] [Abstract][Full Text] [Related]
34. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.
Mirza AZ; Althagafi II; Shamshad H
Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829
[TBL] [Abstract][Full Text] [Related]
35. [The structures and functions of peroxisome proliferator-activated receptors (PPARs)].
Takahashi N; Goto T; Kusudo T; Moriyama T; Kawada T
Nihon Rinsho; 2005 Apr; 63(4):557-64. PubMed ID: 15828220
[TBL] [Abstract][Full Text] [Related]
36. PPAR: a mediator of peroxisome proliferator action.
Green S
Mutat Res; 1995 Dec; 333(1-2):101-9. PubMed ID: 8538617
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
Guan Y; Breyer MD
Kidney Int; 2001 Jul; 60(1):14-30. PubMed ID: 11422732
[TBL] [Abstract][Full Text] [Related]
38. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
Choudhary NS; Kumar N; Duseja A
J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
[TBL] [Abstract][Full Text] [Related]
39. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors.
Lee CH; Olson P; Evans RM
Endocrinology; 2003 Jun; 144(6):2201-7. PubMed ID: 12746275
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
Pirard B
J Comput Aided Mol Des; 2003 Nov; 17(11):785-96. PubMed ID: 15072437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
